From Livogrit to Eyedrop: 14 Patanjali Items Facing Action In Misleading Ads Case | Full List

New Delhi: manufacturing licence of 14 Patanjali's Divya Pharmacy products has been suspended, according to an order issued by Uttarakhand drug licensing authority. order was issued earlier this month taking cognisance of complaints about misleing vertisements of se products by firm in violation of Drugs and Magic Remedies (Objectionable vertisements) Act and Drugs and Cosmetic Act.

firm did not provide information sought from it regarding products and explanation offered by it in its defence was not satisfactory, authority said in its order.  Divya Pharmacy products whose manufacturing licence has been suspended include Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleha, Mukta Vati Extra Power, Lipidom, BP Grit, Mhugrit and Mhunashini Vati Extra Power, according to order.

List of 14 Patanjali Items Facing Action In Misleing s Case

1. Drishti Eye drop
2. Swasari Gold
3. Swasari Vati
4. Bronchom
5. Swasari Pravahi
6. Swasari Avaleh
7. Mukta Vati Extra Power
8. Lipidom
9. Bp Grit
10. Mhugrit
11. Mhunashini Vati Extra Power
12. Livamrit vance
13. Livogrit
14. Eyegrit Gold

Apology For Misleing s

On April 24, Baba Ramdev and Acharya Balkrishna took out anor vertisement in newspapers issuing a second public apology for failing to here to Supreme Court's orders regarding misleing vertisements against Patanjali Ayurved. ir apology was notably larger, likely in response to court's previous scrutiny of size of ir initial apology compared to vertisements for ir products.

Patanjali Ayurved founders Baba Ramdev and managing director Acharya Balkrishna's new “unconditional public apology" in newspapers on April 24 stated, “In wake of on going matter before Hon'ble Supreme Court of India, we in our individual capacity as well as on behalf of Company, unconditionally apologise for non-compliance or disobedience of directions/orders of Hon'ble Supreme Court of India."

Patanjali vs IMA: What Has Happened so Far

Under oversight of Justices Hima Kohli and Ahsanuddin Amanullah, court scrutinises allegations raised by Indian Medical Association (IMA) against Patanjali. One of primary allegations against Patanjali is promotion of products claiming to cure diseases like COVID-19 without scientific substantiation. company has been accused of defaming modern medicine and national COVID-19 vaccination effort, which has been labelled a 'smear campaign'.

During hearing on April 16, Justices Hima Kohli and Ahsanuddin Amanullah expressed dissatisfaction with apologies offered by Patanjali Ayurved's founders, Ramdev and Balkrishna. justices remarked that apologies seemed coerced rar than genuine, reflecting court's firm stance on matter. This case underscores significant ramifications of health product vertisements that make misleing claims about curing diseases without scientific evidence.

This practice is deemed to violate Drugs and Magic Remedies (Objectionable vertisements) Act, of 1954, which prohibits vertising of products with magical or miraculous properties purporting to cure diseases and disorders. Act stipulates penalties including imprisonment for up to one year, fines, or both.

In November 2023, court escalated its involvement by ordering Patanjali to immediately cease all misleing vertisements and impose a penalty of ₹1 crore. court has repeatedly cautioned company against making baseless health claims in its vertisements and has emphasized seriousness of issue.

In February 2024, court dismissed Patanjali's apology affidavit, deeming it insufficient and merely superficial.